Skip to main content
Premium Trial:

Request an Annual Quote

Gualberto Ruano, Richard Judson

Premium

Genaissance Pharmaceuticals CSO Gualberto Ruano will resign from the company on Aug. 31. Ruano, who was ousted from the chief executive’s slot one year ago, will also leave Genaissance’s board of directors. Richard Judson will replace him as CSO.

Judson, 44, joined Genaissance in 1999. Since August 2000 he has served as senior vice president of medical affairs and informatics, and had been responsible for leading the development of the company’s HAP Technology.

He came to Genaissance from CuraGen, where he managed the development of software for protein-protein interactions and DNA-sequence analysis.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.